The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Abstract
Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are unresponsive to standard immunosuppression. We describe the use of daratumumab that induced substantial clinical responses in two patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. Significant depletion of long-lived plasma cells, reduction of interferon type I activity, and down-regulation of T-cell transcripts associated with chronic inflammation were documented. (Supported by the Deutsche Forschungsgemeinschaft and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
The multifaceted biology of plasmacytoid dendritic cells
Swiecki, M., & Colonna, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3865 · Cited by 1,131
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Competence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature Reviews Immunology · doi:10.1038/nri1886 · Cited by 1,030
Self-citationThe immune cell landscape in kidneys of patients with lupus nephritis
the Accelerating Medicines Partnership in SLE network, Arazi, A., Rao, D. A., Berthier, C. C., Davidson, A., Liu, Y., Hoover, P. J., Chicoine, A., Eisenhaure, T. M., Jonsson, A. H., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0398-x · Cited by 827
Kirou, K. A., Lee, C., George, S., Louca, K., Peterson, M. G. E., & Crow, M. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21031 · Cited by 701
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Hiepe, F., Dörner, T., Hauser, A. E., Hoyer, B. F., Mei, H., & Radbruch, A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.1 · Cited by 389
Self-citationAlexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206016 · Cited by 368
Self-citationThe Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 337
Plasma cells as an innovative target in autoimmune disease with renal manifestations
Hiepe, F., & Radbruch, A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.20 · Cited by 209
Self-citationBiesen, R., Demir, C., Barkhudarova, F., Grün, J. R., Steinbrich‐Zöllner, M., Backhaus, M., Häupl, T., Rudwaleit, M., Riemekasten, G., Radbruch, A., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23404 · Cited by 200
Self-citationKatsuyama, E., Suarez-Fueyo, A., Bradley, S. J., Mizui, M., Marin, A. V., Mulki, L., Krishfield, S., Malavasi, F., Yoon, J., Sui, S. J. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.014 · Cited by 159
Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted
Tilstra, J. S., Avery, L., Menk, A. V., Gordon, R. A., Smita, S., Kane, L. P., Chikina, M., Delgoffe, G. M., & Shlomchik, M. J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120859 · Cited by 149
Cole, S., Walsh, A. M., Yin, X., Wechalekar, M. D., Smith, M., Proudman, S., Veale, D. J., Fearon, U., Pitzalis, C., Humby, F., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1578-z · Cited by 133
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation
Chapuy, C. I., Kaufman, R. M., Alyea, E. P., & Connors, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807438 · Cited by 99
Mumtaz, I. M., Hoyer, B. F., Panne, D., Moser, K., Winter, O., Cheng, Q., Yoshida, T., Burmester, G. R., Radbruch, A., Manz, R. A., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.05.010 · Cited by 79
Self-citationAlexander, T., Cheng, Q., Klotsche, J., et al. (2018) · European Journal of Immunology · doi:10.1002/eji.201847492 · Cited by 71
Self-citationCXCR3+CCR5+ T cells and autoimmune diseases: guilty as charged?
Mackay, C. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77837 · Cited by 33
Cited by
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107725 · Cited by 610
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Self-citationCAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Schuermans, A., Pournamdari, A. B., Lee, J., Bhukar, R., Ganesh, S., Darosa, N., Small, A. M., Yu, Z., Hornsby, W., Koyama, S., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00567-0 · Cited by 71
Metadata
- Authors
- Ostendorf, L., Burns, M., Durek, P., Heinz, G. A., Heinrich, F., Garantziotis, P., Enghard, P., Richter, U., Biesen, R., Schneider, U., Knebel, F., Burmester, G., Radbruch, A., Mei, H. E., Mashreghi, M.-F., Hiepe, F., & Alexander, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-17
- Volume
- 383
- Issue
- 12
- Pages
- 1149-1155
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3086471819
- Cited by
- 329
- References
- 21
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.